Elicera corrects CARMA update, says 2 of 3 prior CAR T patients show tumor response, not all 3

Reuters2026/08/14 11:39

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Elicera issued a correction to its Aug. 11 release on the CARMA trial for ELC-301 in relapsed or refractory B-cell lymphoma.
The prior statement wrongly said all three previously CAR T-treated patients had tumor responses; the corrected data show disease control in all three.
Two of those three patients achieved an objective tumor response; one achieved a complete metabolic response.
Top-line one-month readout remains: overall response rate 91% (10 of 11), complete metabolic response 55% (6 of 11), disease control 100%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicera Therapeutics AB published the original content used to generate this news brief on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Elicera corrects CARMA update, says 2 of 3 prior CAR T patients show tumor response, not all 3

You may also like

Crypto prices